Immuneering (IMRX) vs Vicore Pharma AB (VCRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vicore Pharma AB is the larger company by market cap ($246.4 million vs $240.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMRX | VCRE |
|---|---|---|
| Share price | $3.72 | $8.75 |
| Market cap | $240.35M | $246.44M |
| 1-day change | -3.76% | +1.04% |
| YTD return | -41.34% | — |
| 1-year return | -36.82% | — |
| 5-year return | -84.47% | — |
| EPS (TTM) | $-0.93 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.48 | $17.80 |
| 52-week low | $3.60 | $7.88 |
| Distance from 52-week high | -56.19% | -50.84% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +362.18% | +278.97% |
| Average volume | 694.54K | 16.24K |
| Shares outstanding | 64.70M | 28.16M |
| Employees | 57 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Immuneering
IMRX stock →Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Vicore Pharma AB
VCRE stock →Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 46 employees
IMRX vs VCRE FAQ
Which is bigger, Immuneering or Vicore Pharma AB?
Vicore Pharma AB (VCRE) is larger, with a market capitalization of $246.44M compared with $240.35M for Immuneering (IMRX).
Are Immuneering and Vicore Pharma AB in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.